High-versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: An economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial

American Journal of Managed Care

Volumn 9, Issue 6, 2003, Pages 417-424

  Schwartz, J Sanford ^a,b   Wang, Y Richard ^a,e   Cleland, John G F ^c   Gao, Longlong ^a   Weiner, Mark ^a   Poole Wilson, Philip A ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF HULL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSIS RELATED GROUP; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG UTILIZATION; ECONOMIC ASPECT; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICARE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; SENSITIVITY ANALYSIS; SURVIVAL; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; LISINOPRIL; MALE; MIDDLE AGED; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 0037774635     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
2. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
3. ACC/AHA Task Force on Practice Guidelines. Guidelines for the evaluation and management of heart failure. Circulation. 1995;92:2764-2784.
4. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J. 1997;18:736-753.
5. World Health Organization Council on Geriatric Cardiology. Task Force on Heart Failure Education. Concise guide to the management of heart failure. J Card Failure. 1996;2:153-154.
6. Packer M, Cohn JN. Consensus recommendations for the management of congestive heart failure. Am J Cardiol. 1999;83:1A-38A.
7. Cleland JGF, Poole-Wilson PA. ACE inhibitors for heart failure: A question of dose. Br Heart J. 1994;72(suppl 3):S106-S110.
8. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol. 1996;28:1323-1327.
9. Philbin EF, Andreaou C, Rocco TA, Lynch LJ, Baker SL. Patterns of angiotensin converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol. 1996;77:832-838.
10. Smith NL, Psaty BM, Pitt B, Garg R, Gottdiener JS, Heckbert SR. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting inhibitors in older adults, 1989 through 1995. Arch Intern Med. 1998;158:1074-1080.
11. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low-dose and high-doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Atlas Study Group. Circulation. 1999;100:2312-2318.
12. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness Analysis in Health and Medicine. New York: Oxford University Press, 1996.
13. Etzioni RD, Feuer EJ, Sullivan SD, Lin D, Hu C, Ramsey SD. On the use of survival analysis techniques to estimate medical care costs. J Health Econ. 1999;18:365-380.
14. St. Anthony's DRG Guidebook 1999. Reston, Virginia: St. Anthony Publishing, Inc., 1998.
15. 1999 Drug Topics Red Book, July 1999 Update. Montvale, New Jersey: Medical Economics Company, Inc., 1999.
16. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: An example from a randomized trial. Stat Med. 1996;15:1447-1458.
17. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: A comparison of four methods. Health Econ. 1997;6:243-252.
18. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Econ. 1997;6:327-340.
19. American Heart Association. 1998 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 1998.
20. National Heart Lung and Blood Institute. Congestive Heart Failure in the United States: A New Epidemic. Bethesda, MD: US Department of Health and Human Services; 1996.
21. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc. 1997;45:968-974.
22. Graves EJ, Owings MF. 1995 Summary: National Hospital Discharge Survey. Hyattsville, MD: National Center for Health Statistics; 1997. Advance Data From Vital and Health Statistics, No. 291.
23. Captopril Multicenter Study Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol. 1983;2:755-763.
24. Chalmers JP, West MJ, Cyran J, et al. Placebo-controlled study of lisinopril in congestive heart failure: A multicenter study. J Cardiovasc Pharmacol. 1987;9(suppl 3):S89-S97.
25. Paul SD, Kuntz KM, Eagle KA, Weinstein MC. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med. 1994;154:1143-1149.
26. Kleber FX. Socioeconomic aspects of ACE inhibition in the secondary prevention in cardiovascular diseases. Am J Hypertens. 1994;7(suppl 9, pt 2);112S-116S.
27. Tsevat J, Duke D, Goldman L, et al. Cost effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol. 1995;26:914-919.
28. Butler JRG, Fletcher PJ. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. Aust N Z J Med. 1996;26:89-95.
29. Marius-Nunez AL, Heaney L, Fernandez RN, et al. Intermittent inotropic therapy in an outpatient setting: A cost-effective therapeutic modality in patients with refractory heart failure. Am Heart J. 1996;132:805-808.
30. Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G. Cost-effectiveness of carvedilol for heart failure. Am J Cardiol. 1999;83:890-896.
31. Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: The case of heart failure. Arch Intern Med. 1999;159:1690-1700.